QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
QQQ   304.37 (-1.78%)
AAPL   151.92 (-1.77%)
MSFT   266.73 (-0.31%)
META   183.43 (-4.27%)
GOOGL   99.37 (-7.68%)
AMZN   100.05 (-2.02%)
TSLA   201.29 (+2.28%)
NVDA   222.05 (+0.14%)
NIO   10.65 (-2.47%)
BABA   105.11 (-0.37%)
AMD   84.69 (-1.42%)
T   19.16 (-0.47%)
F   13.42 (-0.22%)
MU   60.25 (-3.03%)
CGC   2.74 (-2.84%)
GE   81.96 (-0.18%)
DIS   111.78 (+0.13%)
AMC   5.72 (-7.44%)
PFE   43.98 (+0.89%)
PYPL   79.72 (-4.22%)
NFLX   366.83 (+1.07%)
NASDAQ:QURE

uniQure - QURE Stock Forecast, Price & News

$22.15
-0.77 (-3.36%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$22.04
$22.90
50-Day Range
$20.64
$26.29
52-Week Range
$12.52
$28.25
Volume
311,019 shs
Average Volume
538,566 shs
Market Capitalization
$1.04 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.17

uniQure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
112.9% Upside
$47.17 Price Target
Short Interest
Bearish
7.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$737,780 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.57) to ($1.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

810th out of 1,026 stocks

Pharmaceutical Preparations Industry

402nd out of 504 stocks

QURE stock logo

About uniQure (NASDAQ:QURE) Stock

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

QURE Stock News Headlines

I Love Gold…
There are essentially two ways to invest in gold… The first is simply buying physical gold. But, I want to show you one of our favorite ways to own gold stocks… Click Here For the Details pixel
Amazon has a unique inflation problem - Reuters
Predict These Market Breakouts with A.I.
We’re looking for breakouts using a simple A.I. tool that you've got to see in our Live Free A.I. Market Training. Breakouts can make or break your trading, so it's critical you know how to predict them 1 - 3 days ahead. They happen at any moment, and they're easier to find with A.I. on your side. pixel
uniQure: Betting On Hemophilia-B Cure - Seeking Alpha
See More Headlines
Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

QURE Company Calendar

Last Earnings
10/24/2021
Today
2/08/2023
Next Earnings (Estimated)
2/24/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QURE
Employees
463
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.17
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+112.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$329.59 million
Net Margins
-204.12%
Pretax Margin
-206.73%

Debt

Sales & Book Value

Annual Sales
$524 million
Cash Flow
$7.19 per share
Book Value
$12.89 per share

Miscellaneous

Free Float
45,364,000
Market Cap
$1.04 billion
Optionable
Optionable
Beta
1.09

Key Executives

  • Matt Kapusta
    Chief Executive Officer & Executive Director
  • Pierre Caloz
    Chief Operating Officer
  • Christian KlemtChristian Klemt
    Chief Financial Officer
  • Ricardo DolmetschRicardo Dolmetsch
    President-Research & Development
  • Richard Porter
    Chief Business Officer













QURE Stock - Frequently Asked Questions

Should I buy or sell uniQure stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QURE shares.
View QURE analyst ratings
or view top-rated stocks.

What is uniQure's stock price forecast for 2023?

6 brokers have issued twelve-month price targets for uniQure's stock. Their QURE share price forecasts range from $24.00 to $65.00. On average, they expect the company's share price to reach $47.17 in the next year. This suggests a possible upside of 112.9% from the stock's current price.
View analysts price targets for QURE
or view top-rated stocks among Wall Street analysts.

How have QURE shares performed in 2023?

uniQure's stock was trading at $22.67 at the start of the year. Since then, QURE shares have decreased by 2.3% and is now trading at $22.15.
View the best growth stocks for 2023 here
.

When is uniQure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 24th 2023.
View our QURE earnings forecast
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) announced its quarterly earnings results on Sunday, October, 24th. The biotechnology company reported ($0.79) EPS for the quarter, beating analysts' consensus estimates of ($1.05) by $0.26. The biotechnology company earned $2 million during the quarter, compared to the consensus estimate of $2.13 million. uniQure had a negative trailing twelve-month return on equity of 24.47% and a negative net margin of 204.12%. The business's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.21) earnings per share.

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a variety of retail and institutional investors. Top institutional investors include International Biotechnology Trust PLC (1.35%), Privium Fund Management B.V. (0.64%), Nordea Investment Management AB (0.61%), Banque Pictet & Cie SA (0.58%), China Universal Asset Management Co. Ltd. (0.28%) and UBS Group AG (0.27%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Paula Soteropoulos, Pierre Caloz, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends
.

How do I buy shares of uniQure?

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $22.15.

How much money does uniQure make?

uniQure (NASDAQ:QURE) has a market capitalization of $1.04 billion and generates $524 million in revenue each year. The biotechnology company earns $329.59 million in net income (profit) each year or ($2.69) on an earnings per share basis.

How many employees does uniQure have?

The company employs 463 workers across the globe.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The official website for the company is www.uniqure.com. The biotechnology company can be reached via phone at (120) 240-6000, via email at investors@uniqure, or via fax at 31-20-566-9272.

This page (NASDAQ:QURE) was last updated on 2/8/2023 by MarketBeat.com Staff